权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Core F: Biomarker Core

核心 F：生物标志物核心

基本信息

批准号：
10652573
负责人：
LEE E. GOLDSTEIN
金额：
$ 33.13万
依托单位：
BOSTON UNIVERSITY MEDICAL CAMPUS
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-08-15 至 2026-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10652573
关键词：
Address Ally Alzheimer&apos s Disease Alzheimer&apos s disease related dementia Alzheimer’s disease biomarker Amyloid Amyloid beta-Protein Atrophic Biological Markers Biometry Blood Boston Brain imaging Cells Cerebrum Clinical Clinical Research Collaborations Communities Data Dementia Detection Development Diagnosis Differential Diagnosis Disease Doctor of Medicine Doctor of Philosophy Early Diagnosis Early Intervention Early treatment Education Emerging Technologies Faculty Generations Goals Hippocampus Human Image Imaging Techniques Institution International Ligand Binding Light Liquid substance MRI Scans Magnetic Resonance Imaging Measures Mentorship Mission Molecular Profiling Monitor National Institute on Alcohol Abuse and Alcoholism Nerve Degeneration Neurobehavioral Manifestations Neurodegenerative Disorders Neurons Participant Peptides Plasma Positron-Emission Tomography Postdoctoral Fellow Process Protocols documentation Qualifying Research Research Personnel Resources Risk Assessment Scientist Serum Specimen Staging Targeted Research Testing Therapeutic Thick Training United States National Institutes of Health Universities Update Ventricular accurate diagnosis biomarker development biomarker discovery biomarker validation brain volume chronic traumatic encephalopathy clinical development cohort cost effective data management data sharing early-career faculty education research entorhinal cortex exosome experience genetic profiling improved insight interest member multimodality neurofilament neuroimaging neuroimaging marker neuropathology next generation normal aging novel personalized medicine pre-clinical prevent research clinical testing response statistics tau Proteins tau-1 white matter

项目摘要

Biomarkers provide important information for early detection, differential diagnosis, and disease monitoring of Alzheimer’s disease (AD) and AD-related dementias (ADRDs), including chronic traumatic encephalopathy (CTE). The newly established Biomarker Core of the Boston University Alzheimer’s Disease Research Center (BU ADRC) will be led by three clinician-scientists with experience in biomarker development and validation: Lee Goldstein, M.D., Ph.D. and Wendy Qiu, M.D., Ph.D., who will serve as co-leaders, and Ronald Killiany, Ph.D., who will lead the neuroimaging component. The Biomarker Core will leverage their expertise and existing institutional resources to focus on fluid biospecimen and neuroimaging biomarkers relevant to Alzheimer’s disease (AD) and related dementias (ADRD), including chronic traumatic encephalopathy (CTE). The goal of the Biomarker Core is to collaborate with other cores and centralize biomarker initiatives to support the BU ADRC mission to improve early and accurate diagnosis, differentiation, and monitoring of AD and ADRDs, including CTE. The new Biomarker Core will bank, distribute, and analyze fluid biospecimens and neuroimaging data for shared use by investigators within and outside the BU ADRC and allied national consortia. We will focus on established biofluid and neuroimaging biomarkers (Amyloid-Tau-Neurodegeneration A/T/N NIA-AA Research Framework) with the goal of identifying differences between AD and ADRDs. The Core will also conduct discovery-based development of novel emerging biofluid and neuroimaging biomarkers to enable earlier and more accurate detection, differential diagnosis, staging, and tracking of AD and ADRDs across the disease spectrum. Four Specific Aims are proposed. Aim 1: Process, bank, and distribute fluid biospecimens and neuroimaging data. Aim 2: Measure and analyze established biomarkers (A/T/N NIA-AA Research Framework). Aim 3: Conduct discovery and development of emerging biomarkers, including analysis of blood-derived exosomes and multimodal computational strategies for neuroimaging data. Aim 4: Train next-generation AD biomarker and neuroimaging research leaders. We anticipate that the new Biomarker Core will strengthen BU ADRC research, promote sharing of fluid and neuroimaging biomarker resources, harmonize with efforts to advance national AD/ADRD initiatives, and provide new new insights and biometrics for personalized medicine approaches to diagnose, treat, and prevent AD and ADRD.

生物标志物为早期发现、鉴别诊断和疾病监测提供了重要信息